There are currently 2863 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
NCT04964518
Recruiting
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy and PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and dose expansion phase (Part II)
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
10/23/2023
Locations: MDACC, Houston, Texas
Conditions: AML, Adult
Register for Updates
Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction
NCT06059066
Recruiting
The purpose of this study is to evaluate and standardize the way providers perform OnabotulinumtoxinA (BTX-A) injections into the bladder for the diagnosis of neurogenic lower urinary tract dysfunction (NLUTD)/overactive bladder (OAB). NLUTD/OAB is a syndrome that affects many people, and includes urinary frequency, urinary urgency, urgency incontinence, and nocturia. This syndrome can be challenging to treat and often requires procedural management - including BTX-A injections into the bladder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/20/2023
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Register for Updates
Adaptation of Critical Time Intervention for Young Adults With MH Challenges
NCT06102850
Recruiting
Young adults experiencing homelessness have high rates of mental health conditions but low rates of service utilization and the point of transition from homelessness to supported housing provides a window of opportunity for intervention. The goal of this study is to adapt the evidenced-based intervention, Critical Time Intervention, for young adults with mental health conditions who are entering a rapid rehousing program and test the adapted intervention in a randomized feasibility pilot trial.... Read More
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
10/20/2023
Locations: Covenant House Texas, Houston, Texas
Conditions: Mental Disorder
Register for Updates
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
NCT06056323
Recruiting
This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0045. The phase I study will enroll up to 54 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined as 21 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: UT M.D. Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor, Adult
Register for Updates
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
NCT04858776
Recruiting
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and imp... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
10/17/2023
Locations: University of Texas, Houston, Houston, Texas
Conditions: Iliofemoral; Thrombosis
Register for Updates
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
NCT05586971
Recruiting
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/17/2023
Locations: Pioneer Research Solutions, Inc., Houston, Texas
Conditions: Gout, Hyperuricemia, Gout Flare, Tophi
Register for Updates
EASE: The Materna Prep Pivotal Study
NCT03973281
Recruiting
This study is designed to evaluate the safety and effectiveness of the Materna Prep Device in reducing pelvic muscle injuries during vaginal delivery. Subjects are randomized to Materna Prep Device or Standard of Care without use of the Materna Prep Device Intervention with the Materna Prep Device is expected to be a one-time use of approximately 30-90 minutes during the 1st stage of labor. Subject participation in the study is targeted to be 12 months from the time of the use of the device d... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Vaginal Delivery, Pelvic Organ Prolapse
Register for Updates
Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis
NCT01315782
Recruiting
This is an observational study to understand the changes in alveolar dead space in medical critically ill patients with severe infection (severe sepsis) requiring mechanical ventilation and the possibility to predict multi-organ failure. The measurement of alveolar dead space used to require sophisticated equipment and time. New ventilators have microprocessors that allow rapid mathematical calculation with minimal intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2023
Locations: Memorial Hermann Hospital, Houston, Texas
Conditions: Sepsis, Severe Sepsis, Septic Shock, Multi-organ Failure
Register for Updates
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
NCT04042831
Recruiting
This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Bile Duct Adenocarcinoma, Fanconi Anemia Complementation Group Gene Mutation, Metastatic Bile Duct Carcinoma, PTEN Gene Deletion
Register for Updates
Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
NCT06051669
Recruiting
This is a multi-center, cross-sectional, and prospective study that will recruit patients from multiple hospitals or outpatient clinics in the USA to the comparison of iLivTouch and FibroScan for the assessment of liver fibrosis and steatosis in adult patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2023
Locations: Baylor University, Houston, Texas
Conditions: Liver Fibrosis, Fatty Liver
Register for Updates
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05211570
Recruiting
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
Register for Updates
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
NCT04759664
Recruiting
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: EGFRI Induced Acneiform Lesions
Register for Updates